Business Context and Reporting Period
This Form 8-K filing by MiMedx Group, Inc. reports a corporate governance event dated May 1, 2020, with the report filed on May 5, 2020. The filing focuses on the appointment of a new senior executive officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to the compensation package for the newly appointed officer:
- Annual Base Salary: $350,000
- Target Annual Incentive: 40% of base salary
- Target Long-Term Incentive: 70% of base salary
- Restricted Stock Unit Grant: $350,000 value (vests pro rata over three years)
- Performance-Based Restricted Stock Unit Grant: $150,000 value (vests based on three discrete performance goals)
Material Changes
The primary material change is the appointment of William L. Phelan as Senior Vice President and Chief Accounting Officer, effective May 1, 2020. Mr. Phelan previously served as Interim Controller for the Company from June 2018 to April 2020 while employed by CFGI, a firm providing accounting and compliance services.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, outlook, or discussion of general business risks. The only contingency noted regarding the equity grants is that they will be settled in shares of common stock based on the closing stock price thirty days after the Company first becomes current in its obligations with the Securities and Exchange Commission.
Investor Verification Checklist
- Verify the Company's current status regarding SEC reporting obligations to determine the settlement date for Mr. Phelan's equity grants.
- Confirm the specific discrete performance goals attached to the $150,000 performance-based restricted stock unit grant.
- Review the attached press release (Exhibit 99.1) for any additional context on the leadership transition.